Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Combining Ketamine With Dialectical Behavioural Therapy (DBT) for Suicidality in Individuals With Treatment-Resistant Depression and Borderline Personality Disorder: A Phase II Randomized, Midazolam-Controlled Clinical Trial (KET-DBT)

NCT07569198 is registered in ClinicalTrials.gov with Joshua Rosenblat as lead sponsor.

NCT NCT07569198
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07569198 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Combining Ketamine With Dialectical Behavioural Therapy (DBT) for Suicidality in Individuals With Treatment-Resistant Depression and Borderline Personality Disorder: A Phase II Randomized, Midazolam-Controlled Clinical Trial (KET-DBT)
Lead sponsor
Joshua Rosenblat
Phase
Phase 2
Overall status
Recruiting
Start date
July 16, 2026
Completion date
August 31, 2029
Enrollment
120 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bipolar disorder (bd), bipolar disorder i or ii, borderline personality disorder (bpd), major depressive disorder (mdd), suicidal ideation, treatment-resistant bipolar depression, treatment-resistant major depressive disorder